Write what you believe about your stocks; every morning the cited record grades it: supported, challenged, or untouched. Never opinions.

Development · 11 Nov 2026

Gland Pharma reported Q2 FY27 results with consolidated net profit rising 58.3% YoY to Rs 290.8 crore from Rs 183.7 crore in Q2 FY26.

5 publishers have reported this development. Each act of reporting is below, cited.

The record

Gland Pharma reported Q2 FY27 results with consolidated net profit rising 58.3% YoY to Rs 290.8 crore from Rs 183.7 crore in Q2 FY26.

Gland Pharma reported a 58.2% year-on-year jump in net profit to ₹ 291 crore for the second quarter of FY27.

livemint.com9 Nov 2026

Gland Pharma reported a 58.29 per cent rise in consolidated net profit to Rs 290.75 crore in the September quarter.

Gland Pharma reported a 58.2% year-on-year increase in net profit to ₹291 crore in Q2FY27, compared with ₹184 crore in the corresponding quarter of the previous fiscal year.

cnbctv18.com9 Nov 2026

Drugmaker Gland Pharma Ltd reported a 58.2% year-on-year increase in net profit to ₹291 crore for the second quarter of FY27, compared with ₹184 crore in the corresponding period last year.

cnbctv18.com6 Nov 2026

Every claim carries its citation

This page is the corroborated record of one development: what each credible source reported, linked and dated. We compile and cite; we do not opine.

New here? The reader's guide explains every page, plate by plate.

fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.